TransMedics (TMDX) Liabilities and Shareholders Equity (2018 - 2026)

TransMedics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 71.32% year-over-year to $1.4 billion in Q1 2026; TTM through Mar 2026 was $4.3 billion, a 36.22% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 32.87% from the prior year.
• Liabilities and Shareholders Equity grew to $1.4 billion in Q1 2026 per TMDX's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.4 billion in Q1 2026 and bottomed at $117.3 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $723.8 million (2024), against an average of $671.5 million.
• Across the five-year window, Liabilities and Shareholders Equity fell 16.53% in 2022 and surged 488.62% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $277.1 million in 2022, then soared by 154.76% to $706.0 million in 2023, then rose by 13.88% to $804.1 million in 2024, then surged by 32.87% to $1.1 billion in 2025, then surged by 34.3% to $1.4 billion in 2026.
• Per Business Quant, the three latest TMDX Liabilities and Shareholders Equity figures stand at $1.4 billion (Q1 2026), $1.1 billion (Q4 2025), and $946.0 million (Q3 2025).